Sofosbuvir/Velpatasvir and Rosuvastatin/Ezetimibe Interaction

Understanding the Sofosbuvir/Velpatasvir and Rosuvastatin/Ezetimibe Interaction

FDA-approved prescribing information for these two drugs flags their combination as a major-severity interaction. Sofosbuvir/Velpatasvir belongs to the NS5B/NS5A Inhibitor (HCV) class and Rosuvastatin/Ezetimibe belongs to the Statin / Cholesterol Absorption Inhibitor class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: This antiviral medicine increases the amount of rosuvastatin in your system by changing how your body processes it. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Sofosbuvir/Velpatasvir has 33 total documented interactions on file in this dataset, and Rosuvastatin/Ezetimibe has 12. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: You should start with a low 5 mg dose of rosuvastatin and never take more than 10 mg daily while using this combination. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Sofosbuvir/Velpatasvir or Rosuvastatin/Ezetimibe based on a web page, speak with your prescriber or pharmacist before making any change.